留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

器官移植术后丙型肝炎病毒感染诊疗规范(2019版)

中华医学会器官移植学分会

中华医学会器官移植学分会. 器官移植术后丙型肝炎病毒感染诊疗规范(2019版)[J]. 器官移植, 2019, 10(3): 249-252. doi: 10.3969/j.issn.1674-7445.2019.03.005
引用本文: 中华医学会器官移植学分会. 器官移植术后丙型肝炎病毒感染诊疗规范(2019版)[J]. 器官移植, 2019, 10(3): 249-252. doi: 10.3969/j.issn.1674-7445.2019.03.005
Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specifcation for hepatitis C virus infection after organ transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 249-252. doi: 10.3969/j.issn.1674-7445.2019.03.005
Citation: Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specifcation for hepatitis C virus infection after organ transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 249-252. doi: 10.3969/j.issn.1674-7445.2019.03.005

器官移植术后丙型肝炎病毒感染诊疗规范(2019版)

doi: 10.3969/j.issn.1674-7445.2019.03.005
基金项目: 

国家自然科学基金 81570680

国家自然科学基金 81571555

详细信息
    通讯作者:

    石炳毅,中国人民解放军总医院第八医学中心,Email:shibingyi666@126.com;孙丽莹,首都医科大学附属北京友谊医院,Email:sunxlx@outlook.com

  • 中图分类号: R617, R512.6

Diagnosis and treatment specifcation for hepatitis C virus infection after organ transplantation (2019 edition)

  • 摘要: 为了进一步规范实体器官移植(SOT)术后丙型肝炎病毒(HCV)感染的诊断和治疗,中华医学会器官移植学分会组织器官移植专家和感染病学专家,从流行病学、SOT术后HCV感染的诊断、SOT术后HCV感染的预防和治疗等方面,制订本规范,以帮助器官移植工作者规范和优化HCV感染的诊断和治疗。
  • [1] LANINI S, PISAPIA R, CAPOBIANCHI MR, et al. Global epidemiology of viral hepatitis and national needs for complete control[J]. Expert Rev Anti Infect Ther, 2018, 16(8):625-639. DOI: 10.1080/14787210.2018.1505503.
    [2] 苏迎盈, 刘慧鑫, 汪宁.中国丙型肝炎病毒基因型分布[J].中华流行病学杂志, 2013, 34(1):80-84. DOI: 10.3760/cma.j.issn.0254-6450.2013.01.019.

    SUN YY, LIU HX, WANG N. Hepatitis C virus genotypes in China: a systematic review[J]. Chin J Epidemiol, 2013, 34(1):80-84.DOI: 10.3760/cma.j.issn.0254-6450.2013.01.019.
    [3] WONG MCS, HUANG JLW, GEORGE J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(1):57-73. DOI: 10.1038/s41575-018-0055-0.
    [4] 陈园生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32(9):888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009.

    CHEN YS, LI L, CUI FQ, et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol, 2011, 32(9):888-891.DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009.
    [5] COILLY A, ROCHE B, SAMUEL D. Current management and perspectives for HCV recurrence after liver transplantation[J].Liver Int, 2013, 33(Suppl 1):56-62. DOI: 10.1111/liv.12062.
    [6] DOMÍNGUEZ-GIL B, MORALES JM. Transplantation in the patient with hepatitis C[J]. Transpl Int, 2009, 22(12):1117-1131. DOI: 10.1111/j.1432-2277.2009.00926.x.
    [7] FORMAN LM, LEWIS JD, BERLIN JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation[J]. Gastroenterology, 2002, 122(4):889-896. doi: 10.1053/gast.2002.32418
    [8] HEIDRICH B, PISCHKE S, HELFRITZ FA, et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients[J]. J Viral Hepat, 2014, 21(11):769-779. DOI: 10.1111/jvh.12204.
    [9] ALONSO R, PÉREZ-GARCÍA F, LÓPEZ-ROA P, et al. HCV core-antigen assay as an alternative to HCV RNA quantification: a correlation study for the assessment of HCV viremia[J]. Enferm Infecc Microbiol Clin, 2018, 36(3):175-178. DOI: 10.1016/j.eimc.2016.11.013.
    [10] FABRIZI F, AGHEMO A, MESSA P. Hepatitis C treatment in patients with kidney disease[J]. Kidney Int, 2013, 84(5):874-879. DOI: 10.1038/ki.2013.264.
    [11] BURRA P, RODRÍGUEZ-CASTRO KI, MARCHINI F, et al. Hepatitis C virus infection in end-stage renal disease and kidney transplantation[J]. Transpl Int, 2014, 27(9):877-891. DOI: 10.1111/tri.12360.
    [12] Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl, 2008(109):S1-S99. DOI: 10.1038/ki.2008.81.
    [13] CIESEK S, PROSKE V, OTTO B, et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation[J].Transpl Infect Dis, 2016, 18(3):326-332. DOI: 10.1111/tid.12524.
    [14] TERRAULT NA, STOCK PG. Management of hepatitis C in kidney transplant patients: on the cusp of change[J]. Am J Transplant, 2014, 14(9):1955-1957. DOI: 10.1111/ajt.12848.
    [15] LIN MV, SISE ME, PAVLAKIS M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection[J]. PLoS One, 2016, 11(7):e0158431. DOI: 10.1371/journal.pone.0158431.
    [16] KIEFFER TL, SARRAZIN C, MILLER JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients[J]. Hepatology, 2007, 46(3):631-639. doi: 10.1002/hep.v46:3
    [17] FABRIZI F, MARTIN P, MESSA P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant[J]. Kidney Int, 2016, 89(5):988-994. DOI: 10.1016/j.kint.2016.01.011.
    [18] MORALES JM, FABRIZI F. Hepatitis C and its impact on renal transplantation[J]. Nat Rev Nephrol, 2015, 11(3):172-182. DOI: 10.1038/nrneph.2015.5.
    [19] Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl, 2018, 8(3):91-165. DOI: 10.1016/j.kisu.2018.06.001.
    [20] XUE W, PAN D, YANG Y, et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435[J]. Antiviral Res, 2012, 93(1):126-137. DOI: 10.1016/j.antiviral.2011.11.007.
    [21] WALKER A, FILKE S, LÜBKE N, et al. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure[J]. Virol J, 2017, 14(1):106. DOI: 10.1186/s12985-017-0779-4.
    [22] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [M]. Geneva: World Health Organization, 2018: 1-83.
  • 加载中
计量
  • 文章访问数:  27
  • HTML全文浏览量:  0
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-01-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2019-05-15

目录

    /

    返回文章
    返回